GE HealthCare Technologies Inc. delivered its fourth quarter and full-year 2025 financial results, demonstrating revenue growth across key segments and resilience amid global trade challenges. The company’s performance reflected solid demand in diagnostic imaging, pharmaceutical diagnostics and advanced visualization …
AbbVie Inc. announced financial results for the full year and fourth quarter ended December 31, 2025, delivering modest revenue growth and operational progress across key therapeutic portfolios. The company also provided earnings guidance for 2026, reflecting confidence in its diversified platform amid an evolving com…
Eli Lilly and Company reported robust financial results for the fourth quarter ended December 31, 2025, driven by accelerating demand for its leading diabetes and obesity therapies and solid operational execution. The company also provided financial guidance for the full year 2026, signaling continued growth momentum.…
Swiss life sciences specialist Lonza Group AG reported a robust set of full-year 2025 results, driven by strong demand across its contract development and manufacturing (CDMO) business and successful integration of the Vacaville site, under the leadership of CEO Wolfgang Wienand. Lonza delivered significant sales grow…
CEO Luke Miels, GSK delivered a strong set of FY 2025 results, with group sales rising to £32.7 billion, up 7 % at constant exchange rates (CER), and broad progress across Specialty Medicines and vaccines driving profitability and cash generation. The company also reaffirmed long-term growth targets while outlining a …
Under the leadership of CEO Vas Narasimhan, Swiss pharma group Novartis reported robust full-year 2025 financial results, achieving high single-digit sales growth and significant expansion in core profitability, while setting the stage for a challenging 2026 outlook amid pending patent expirations. Net sales for the y…
Swiss healthcare giant Roche reported its full-year 2025 financial performance, highlighting resilient sales growth across its pharmaceuticals and diagnostics businesses under CEO Thomas Schinecker’s leadership. The company delivered a 7% increase in group sales at constant exchange rates (CER) to CHF 61.5 billion, dr…
Pfizer Inc. announced its fourth quarter and full-year 2025 financial results and reaffirmed its full-year 2026 guidance, reporting solid earnings performance amid an evolving product mix and continued transition from COVID-19 related revenues. Dr. Albert Bourla, Chairman and Chief Executive Officer, underscored the c…
Teva Pharmaceutical Industries Ltd. reported fourth quarter and full-year 2025 financial results, underscoring a profitable Q4 performance and continued execution of its “Pivot to Growth” strategy. Richard Francis, President and CEO, characterized the results as a significant milestone in Teva’s transformation, with i…
Amgen Inc. announced strong financial results for the fourth quarter and full year of 2025, reflecting broad product demand, volume-driven growth and disciplined investment in innovation, the company said in its latest earnings release. Robert A. Bradway, chairman and chief executive officer, highlighted the company’…
Page 2 of 3